L&G partner, Mathew Lombard has written a second article for Biotechnology Startup Blog. The article is about international trademark filing program strategies and considerations. You can read the article at: http://www.biotechstart.org/?p=1140.
Congratulations, Matt, on your second article for the site!
“As usual you are the absolute best. You have such a keen understanding of things.”
K.J., New York, NY
Mexico has joined the Madrid Protocol.
Accepted on November 19, 2012, the Protocol will become effective on Mexico on February 19, 2013.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 66(A) (Madrid Protocol) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 44(e) (Paris Convention) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 44(d) (Paris Convention priority) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 1(a) use-based application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 1(b) intent-to-use application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
On Tuesday, the FDA announced that it approved the first flu vaccine comprising animal cell cultures. The vaccine, to be marketed under the trademark FLUCELVAX, is a Novartis product. FLUCELVAX will be manufactured in Novartis’ brand new North Carolina plant.
The vaccine is produced with virus strains that are grown in animal cell cultures derived from mammals instead of in chicken eggs. Similar cell culture technology has long been used to produce other types of vaccines, FDA said.
FDA press release here.